Sarepta and FDA Clash Over Duchenne Treatment, Leaving Families in Limbo
Key Takeaways: The approval of a groundbreaking gene therapy for Duchenne muscular dystrophy faced unexpected setbacks. FDA safety concerns led to the immediate halting of treatment deliveries. Families awaiting treatment are left in limbo, dealing with emotional turmoil and uncertainty. Communication from manufacturers and regulators is crucial in managing the anxiety of affected families. In …